HX301+/Temozolomide
Phase 2Small molecule
HX301+/Temozolomide is one of 9 small molecule programs targeting Phase 2. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
9 competitors in Phase 2
#DrugCompanyPhaseTrials
1Suboxone
IIndivior Inc.
Approved
Vizimpro
PfizerPhase 2
P1101
PPharmaEssentia Japan K.K.
Phase 3
ABSK061
AAbbisko Therapeutics Co, Ltd
Phase 2
ABSK-011
AAbbisko Therapeutics Co, Ltd
Phase 2
Taletrectinib
Innovent Biologics (Suzhou) Co. Ltd.Phase 2
TRS005
ZZhejiang Teruisi Pharmaceutical Inc.
Phase 2
HX301+/Temozolomide
HHangzhou Hanx Biopharmaceuticals, Ltd.
Phase 2
SB17170
SSPARK Biopharma
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HX301+/Temozolomide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details